Predicate |
Object |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4704 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-26 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4704 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-26 |
filingDate |
2009-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate |
2011-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
CN-102264703-A |
titleOfInvention |
Mesylate salt of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino }-1-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one as agonist of the beta 2 adrenergic receptor |
abstract |
The present invention is directed to a mesylate salt of 5-(2-{[6-(2,2-difluoro-2- phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1 H)-one and pharmaceutically acceptable solvates thereof. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103864670-A |
priorityDate |
2008-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |